News | October 15, 2014

AtriCure Completes Enrollment in Post Approval Study for the Synergy Ablation System

Study looks to evaluate effectiveness of surgical ablation procedure for AFib patients

October 15, 2014 — AtriCure, Inc. today announced enrollment in the ABLATE Post Approval Study (PAS) is complete.

As of Oct. 3, 2014, the ABLATE PAS enrolled 365 patients at 40 hospitals across the United States. AtriCure expects to release preliminary data from the study in about a year, with a complete report expected to be published in three years.

The ABLATE PAS evaluates clinical outcomes in patients with non-paroxysmal (persistent or longstanding persistent) forms of atrial fibrillation (AFib) who were treated utilizing the AtriCure Synergy Ablation System to perform the Maze IV procedure. The non-paroxysmal Afib patient group represents about half of the diagnosed patient population and who are extremely challenging to manage with conventional medical therapy or catheter ablation.

“The PAS study is intended to build additional evidence of the safety, efficacy and long-term durability of the Maze IV concomitant treatment for Afib using AtriCure’s proprietary surgical devices,” said Patrick McCarthy, M.D., director of the Bluhm Cardiovascular Institute at Northwestern University Feinberg School of Medicine and lead physician for the ABLATE PAS.

The AtriCure Synergy Ablation System is the first and only medical device to receive Food and Drug Administration (FDA) approval for the treatment of Afib in patients with persistent and long-standing persistent Afib undergoing coronary artery bypass grafting and/or valve replacement or repair.

The initial ABLATE study was completed prior to AtriCure receiving a premarket approval (PMA) for the Synergy Ablation System. This study reported results that showed 84 percent of patients free from Afib at six months following an open concomitant Maze IV treatment, and 75 percent of patients free from Afib and off of anti-arrhythmic pharmaceuticals at a mean follow-up of 22 months when assessed by 48-hour Holter monitors. The intent of the ABLATE PAS study is to demonstrate the positive results from the Maze IV treatment used in the original ABLATE study is reproducible and reliable when performed at hospitals across the country.

More than 2.7 million Americans are living with Afib, a cardiac rhythm disorder that increases in prevalence with age. Afib is responsible for nearly 100,000 deaths and adds $26 billion in expenses to the United States healthcare system each year. Afib is associated with a five-fold increased risk of stroke.

For more information: www.atricure.com

 

Related Content

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo